Novartis NYSE: NVS ZURYCH: NOVN p. farmaceutyczny

[slayer74]

#Novartis has proposed a CHF 3.10 per share dividend for FY 2021, up 3.3% from 2020. This represents the 25th consecutive dividend increase since the creation of Novartis in December 1996. #Switzerland #dividends

[slayer74]

Novartis (SIX:NOVN) stock rose 0.8% after the Swiss drugmaker said it was integrating its pharmaceuticals and oncology units into an innovative medicines business to simplify its structure, targeting savings of at least $1 billion by 2024.

[slayer74]

Novartis (SIX:NOVN Novartis) stock dropped 1.1% following reports the Swiss drugmaker is set to cut thousands of jobs worldwide as part of a reorganization.

[slayer74]

Novartis (SIX:NOVN) posted a 3% rise in core operating income, helped by sales growth from new drugs

[slayer74]

Novartis AG zamierza stworzyć europejskiego lidera leków generycznych. W tym celu zamierza wydzielić jednostkę Sadoz, która ma zająć się produkcją tych medykamentów - pisze Bloomberg.

https://www.pb.pl/novartis-wydzieli-sad ... ie-1159467

[slayer74]

ZURICH (Reuters) - Pharmaceuticals company Novartis plans to close a Sandoz generics plant in Wilson, North Carolina, around the end of 2023, it said on Friday, citing inability to use the U.S. site to full capacity.

The site with about 246 employees specialises in producing pharmaceutical oral solid dosage products for distribution mostly in U.S. and Canadian markets.

It said the decision to close the site had come before it announced a strategic review of Sandoz, which it plans to spin off to sharpen the group's focus on patented prescription medicines.

[slayer74]

Novartis (SIX:NOVN) stock fell 0.4% after the Swiss pharmaceutical giant announced that it is the subject of an investigation by the country’s competition commission into patent use.

[slayer74]

Swiss drugmaker Novartis AG (SIX:NOVN) revealed a drop of 4% in quarterly operating income as competition weighed on prescriptions of multiple sclerosis drug Gilenya

[slayer74]

Drugmaker GSK (LON:GSK) warned that slipping demand for COVID-related products will hit sales growth in 2023 by about 9%, reflecting a move by governments away from pandemic-era procurement programs. But fourth quarter profit beat estimates, thanks to demand for its shingles vaccines, helping shares move up slightly.

But pharmaceutical peer Novartis (SIX:NOVN) saw its shares fall. Quarterly sales were just below expectations due to weakness in demand for its psoriasis treatment Cosentyx.

[slayer74]

Novartis initiates new trading line for share buybacks

(Reuters) -Novartis said on Monday it received regulatory clearance to open a separate trading line for potentially up to 16.5 billion Swiss francs ($18.1 billion) in stock repurchases even as its ongoing $15 billion buyback programme is close to completion.

At last week's annual shareholder meeting, the company won investor authorization for up to 10 billion francs in buybacks, which comes on top of 6.5 billion francs in prior authorizations.

A company spokesperson told Reuters on Monday that the "majority" of its ongoing $15 billion buyback programme was already completed, adding that any repurchases would be decided by the board of directors.

She declined to comment on specific amounts.

Novartis laid out plans for the $15 billion programme in late 2021, after receiving $20.7 billion for the sale of its nearly one-third voting stake in Roche back to its cross-town rival.

The spokesperson said the remainder of that repurchase programme would be carried out while allowing for "bolt-on M&A, whilst providing a strong, growing dividend and reinvesting in the business".

Novartis's CEO Vas Narasimhan said in January that the group was looking at the "full range of M&A opportunities", but the focus was on assets worth no more than $5 billion.

https://www.investing.com/news/stock-ma ... ck-3028474

[slayer74]

Novartis (SIX:NOVN) stock rose over 5% after the Swiss drugmaker received positive news from a trial of its Kisqali breast cancer drug.

[slayer74]

Novartis Stock Hits Record High On A Trio Of First-Quarter Drivers

https://www.investors.com/news/technolo ... s-q1-2023/

[slayer74]

Novartis (SIX:NOVN) stock rose 1.4% after the pharma giant announced earlier Monday plans to acquire U.S.-based Chinook Therapeutics (NASDAQ:KDNY) for $3.2 billion upfront.

[slayer74]

Novartis (SIX:NOVN) sock rose 2.5% after the Swiss drugmaker raised its full-year earnings guidance, citing strong drug sales as it laid out plans for the spin-off of its generic medicines division Sandoz for early in the fourth quarter.